{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:19:51Z","timestamp":1777623591112,"version":"3.51.4"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jvetres-2019-0051_s_005\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in veterinary medicine. They are used in pain control and in anti-inflammatory and antipyretic therapies. Some NSAIDs,\n                      <jats:italic>e.g<\/jats:italic>\n                      piroxicam, also have a documented anticancer effect. The objective of this study was to evaluate which of the commonly used NSAIDs (etodolac, flunixin, tolfenamic acid, carprofen, and ketoprofen) are cytotoxic to the D-17 cell line of canine osteosarcoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jvetres-2019-0051_s_006\">\n                    <jats:title>Material and Methods<\/jats:title>\n                    <jats:p>\n                      The viability of the cells was evaluated using the MTT assay. Four independent repetitions were performed and the results are given as the average of these values; EC\n                      <jats:sub>50<\/jats:sub>\n                      values (half maximal effective concentration) were also calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jvetres-2019-0051_s_007\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analysis of results showed that carprofen and tolfenamic acid displayed the highest cytotoxicity. Other drugs either did not provide such effects or they were very poor. For carprofen, it was possible to determine an EC\n                      <jats:sub>50<\/jats:sub>\n                      which fell within the limits of concentrations obtainable in canine serum after the administration of routinely used doses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jvetres-2019-0051_s_008\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results are promising but further studies should be conducted to confirm them, since this study is only preliminary. The possibility of introducing carprofen and tolfenamic acid into the routine treatment of osteosarcoma in dogs should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/jvetres-2019-0051","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T06:02:50Z","timestamp":1568959370000},"page":"399-403","source":"Crossref","is-referenced-by-count":11,"title":["Effect of selected nonsteroidal anti-inflammatory drugs on the viability of canine osteosarcoma cells of the D-17 line:\n                    <i>in vitro<\/i>\n                    studies"],"prefix":"10.2478","volume":"63","author":[{"given":"Dominik","family":"Poradowski","sequence":"first","affiliation":[{"name":"Division of Animal Anatomy, Department of Biostructure and Animal Physiology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences , 51-631 Wroc\u0142aw , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u017cena","family":"Obmi\u0144ska-Mrukowicz","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences , 50-375 Wroc\u0142aw , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"key":"2026042819455770520_j_jvetres-2019-0051_ref_001","doi-asserted-by":"crossref","unstructured":"Abdelrahim M., Baker C.H., Abbruzzese J.L., Safe S.: Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006, 98, 855\u2013868.","DOI":"10.1093\/jnci\/djj232"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_002","doi-asserted-by":"crossref","unstructured":"Basha R., Ingersoll S.B., Sankpal U.T., Ahmad S., Baker C.H., Edwards J.R., Holloway R.W., Kaja S., Abdelrahim M.: Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011, 122, 163\u2013170.","DOI":"10.1016\/j.ygyno.2011.03.014"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_003","doi-asserted-by":"crossref","unstructured":"Chen W.S., Wei S.J., Liu J.M., Hsiao M., Kou-Lin J., Yang W.K.: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001, 91, 894\u2013899.","DOI":"10.1002\/1097-0215(200102)9999:9999<894::AID-IJC1146>3.3.CO;2-R"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_004","doi-asserted-by":"crossref","unstructured":"Choi E.S., Shim J.H., Jung J.Y., Kim H.J., Choi K.H., Shin J.A., Nam J.S., Cho N.P., Cho S.D.: Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci 2011, 102, 742\u2013748.","DOI":"10.1111\/j.1349-7006.2011.01871.x"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_005","doi-asserted-by":"crossref","unstructured":"Colon J., Basha M.R., Madero-Visbal R., Konduri S., Baker C.H., Herrera L.J., Safe S., Sheikh-Hamad D., Abudayyeh A., Alvarado B., Abdelrahim M.: Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2011, 29, 41\u201351.","DOI":"10.1007\/s10637-009-9331-8"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_006","doi-asserted-by":"crossref","unstructured":"Eslin D., Sankpal U.T., Lee C., Sutphin R.M., Maliakal P., Currier E., Sholler G., Khan M., Basha R.: Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma. Mol Carcinog 2013, 52, 377\u2013386.","DOI":"10.1002\/mc.21866"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_007","doi-asserted-by":"crossref","unstructured":"Grandemange E., Fournel S., Boisram\u00e9 B.: Field evaluation of the efficacy of tolfenamic acid administered in one single preoperative injection for the prevention of postoperative pain in the dog. J Vet Pharmacol Ther 2007, 30, 503\u2013507.","DOI":"10.1111\/j.1365-2885.2007.00899.x"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_008","doi-asserted-by":"crossref","unstructured":"Hillers K.R., Dernell W.S., Lafferty M.H., Withrow S.J., Lana S.E.: Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986\u20132003). J Am Vet Med Assoc 2005, 226, 1364\u20131367.","DOI":"10.2460\/javma.2005.226.1364"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_009","doi-asserted-by":"crossref","unstructured":"Khwaja F.S., Quann E.J., Pattabiraman N., Wynne S., Djakiew D.: Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther 2008, 7, 3539\u20133545.","DOI":"10.1158\/1535-7163.MCT-08-0512"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_010","doi-asserted-by":"crossref","unstructured":"McKellar Q.A., Lees P., Gettinby G.: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol 1994, 253, 191\u2013200.","DOI":"10.1016\/0014-2999(94)90191-0"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_011","doi-asserted-by":"crossref","unstructured":"Mullins M.N., Lana S.E., Dernell W.S., Ogilvie G.K., Withrow S.J., Ehrhart E.J.: Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med 2004, 18, 859\u2013865.","DOI":"10.1111\/j.1939-1676.2004.tb02633.x"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_012","doi-asserted-by":"crossref","unstructured":"Okamoto A., Shirakawa T., Bito T., Shigemura K., Hamada K., Gotoh A., Fujisawa M., Kawabata M.: Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo Urology 2008, 71, 156\u2013160.","DOI":"10.1016\/j.urology.2007.09.061"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_013","doi-asserted-by":"crossref","unstructured":"Pang L.Y., Argyle S.A., Kamida A., Morrison K.O., Argyle D.J.: The long-acting COX-2 inhibitor mavacoxib (Trocoxil\u2122) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro BMC Vet Res 2016, 10, 184.","DOI":"10.1186\/PREACCEPT-9511370941246208"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_014","doi-asserted-by":"crossref","unstructured":"Papineni S., Chintharlapalli S., Abdelrahim M., Lee S.O., Burghardt R., Abudayyeh A., Baker C., Herrera L., Safe S.: Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009, 30, 1193\u20131201.","DOI":"10.1093\/carcin\/bgp092"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_015","doi-asserted-by":"crossref","unstructured":"Rosenberger J.A., Pablo N.V., Crawford P.C.: Prevalence of and intrinsic risk factors for appendicular osteosarcoma in dogs: 179 cases (1996\u20132005). J Am Vet Med Assoc 2007, 231, 1076\u20131080.","DOI":"10.2460\/javma.231.7.1076"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_016","doi-asserted-by":"crossref","unstructured":"Roze M., Thomas E., Davot J.L.: Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics, and clinical results obtained in an experimental model. J Small Anim Pract 1996, 37, 371\u2013375.","DOI":"10.1111\/j.1748-5827.1996.tb02418.x"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_017","doi-asserted-by":"crossref","unstructured":"Ru G., Terracini B., Glickman L.T.: Host related risk factors for canine osteosarcoma. Vet J 1998, 156, 31\u201339.","DOI":"10.1016\/S1090-0233(98)80059-2"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_018","doi-asserted-by":"crossref","unstructured":"Shigemura K., Shirakawa T., Wada Y., Kamidono S., Fujisawa M., Gotoh A.: Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo Urology 2005, 66, 1239\u20131244.","DOI":"10.1016\/j.urology.2005.06.076"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_019","doi-asserted-by":"crossref","unstructured":"Spodnick G.J., Berg J., Rand W.M., Schelling S.H., Couto G., Harvey H.J., Henderson R.A., MacEwen G., Mauldin N., McCaw D.L.: Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978\u20131988). J Am Vet Med Assoc 1992, 200, 995\u2013999.","DOI":"10.2460\/javma.1992.200.07.995"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_020","doi-asserted-by":"crossref","unstructured":"Wilson H., Chadalapaka G., Jutooru I., Sheppard S., Pfent C., Safe S.: Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (Sp) transcription factors, and Sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells. J Vet Intern Med 2012, 26, 977\u2013986.","DOI":"10.1111\/j.1939-1676.2012.00931.x"},{"key":"2026042819455770520_j_jvetres-2019-0051_ref_021","doi-asserted-by":"crossref","unstructured":"Withrow S.J., Vail M.D.: Withrow and MacEwen\u2019s Small Animal Clinical Oncology, edited by S.J. Withrow, D.M. Vail, W.B. Saunders, St. Louis, 2007, p. 71.","DOI":"10.1016\/B978-072160558-6.50013-7"}],"container-title":["Journal of Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/jvetres\/63\/3\/article-p399.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/jvetres-2019-0051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:55:13Z","timestamp":1777416913000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/jvetres-2019-0051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9,13]]},"published-print":{"date-parts":[[2019,9,13]]}},"alternative-id":["10.2478\/jvetres-2019-0051"],"URL":"https:\/\/doi.org\/10.2478\/jvetres-2019-0051","relation":{},"ISSN":["2450-8608"],"issn-type":[{"value":"2450-8608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}